MetaVia ( (MTVA) ) just unveiled an update.
On April 15, 2025, MetaVia Inc. announced positive results from the multiple ascending dose Part 2 of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog agonist aimed at treating obesity. The trial demonstrated significant weight loss and safety effects, with a maximum weight reduction of 6.3% and mean reduction of 4.3% at a 32 mg dose. The study showed promising glucose control and waist reduction, with no serious adverse events reported. MetaVia plans to further explore the drug’s potential in a Phase 1 Part 3 study and additional cohorts to determine the maximum tolerated dose.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.
MetaVia’s overall stock score is significantly impacted by its poor financial performance, with persistent losses and a lack of revenue. The technical analysis suggests a weak market position with no upward momentum. Valuation metrics are unfavorable due to negative earnings, making it a high-risk investment. There is a pressing need for strategic operational improvements.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist.
YTD Price Performance: -12.80%
Average Trading Volume: 29,891
Technical Sentiment Signal: Buy
Current Market Cap: $15.92M
For a thorough assessment of MTVA stock, go to TipRanks’ Stock Analysis page.